IQVIA Q3 2026: revenue up 8% and clinical bookings up 15% to $3.2B, but pretax profit fell 5%

Overview

IQVIA runs two businesses. Research & Development Solutions (R&DS) is a contract research organization (CRO): drug and biotech companies pay it to run their clinical trials. Commercial Solutions sells healthcare data, analytics, software and outsourced sales and patient services to the same companies once their medicines are on the market.

Third-quarter 2026 revenue rose 8.0% to $4,428 million (8.6% at constant currency, meaning at last year's exchange rates, so currency cost about 0.6 points this time). R&DS signed $3.2 billion of net new business, up 15%, which the CEO called the strongest clinical bookings quarter since 2022. GAAP diluted EPS rose 8.8% to $2.10 and IQVIA's adjusted EPS rose 11.3% to $3.34. Management raised its full-year guidance for revenue, Adjusted EBITDA and adjusted EPS again.

The weak spot is underneath the EPS line. Pretax profit fell 5.4%, to $386 million from $408 million. GAAP net income still grew because of a $42 million profit from companies IQVIA part-owns (zero a year ago), and EPS grew faster than net income because IQVIA has 2.7% fewer shares than a year ago.

This analysis is based on IQVIA's earnings release (8-K Exhibit 99.1, filed October 27, 2026). The full 10-Q has not been filed yet, so segment profit, regional detail and management's explanations of what drove each line are not available. This report covers what the release discloses.

Key metrics

Operating margin is the share of revenue left after running the business, before interest and tax. The release gives segment revenue growth rates and the 2026 figures but not the recast 2025 segment amounts, which is why those cells read n/a.

R&DS: bookings strong, backlog reset

R&DS revenue rose 8.7% to $2,639 million (9.1% at constant currency). Part of a CRO's revenue is reimbursed expenses: mainly payments to the hospitals and doctors running trial sites, which IQVIA passes on to clients at little or no margin. Excluding them, R&DS revenue grew 6.8%. Pass-through revenue is still growing faster than IQVIA's own service work, just as it did in Q2 (6.7% vs 8.8% headline).

Net new bookings (new contracts signed, minus cancellations) were $3.2 billion, up 15%, a book-to-bill ratio (bookings divided by revenue) of 1.2x. That follows a record $3.15 billion in Q2, so two quarters in a row IQVIA signed meaningfully more work than it delivered.

The backlog figure needs a footnote. Contracted backlog, signed work not yet performed, was $32.6 billion on September 30, down from $34.2 billion on June 30. The drop is not lost business in the usual sense: IQVIA reviewed trials in its backlog that had gone inactive and took about $2.1 billion out. The release says the adjustment does not affect past results, 2026 guidance, book-to-bill or the next-twelve-months revenue estimate. By our arithmetic, $34.2 billion less $2.1 billion is $32.1 billion, so underlying backlog grew by about $0.5 billion in the quarter, in line with a 1.2x book-to-bill. The write-down does mean that roughly 6% of the backlog IQVIA had been reporting was work unlikely to be done. A reader comparing backlog with other CROs should use the new, lower base.

The more useful number is the $9.4 billion of backlog IQVIA expects to convert to revenue in the next twelve months, up 10%. Three months ago the same measure was $9.2 billion, up 7.5%. Near-term clinical revenue looks to be accelerating, and the CEO said clinical organic growth (excluding acquisitions) was nearly triple last year's rate.

Commercial Solutions: growth slowed

Commercial Solutions revenue rose 6.9% to $1,789 million, or 7.9% at constant currency. That is slower than Q2's 8.6% reported growth, and the segment's revenue was slightly lower than Q2's $1,793 million. Currency, which helped this segment in the first half, cost a full point this quarter. The release gives no segment profit or product-line detail; those come with the 10-Q.

What the headline numbers hide

Operating profit grew less than half as fast as revenue. Revenue rose $328 million, but income from operations rose only $19 million, so operating margin slipped to 12.9% from 13.5%. Three costs grew faster than sales:

Within depreciation and amortization, amortization of acquired intangibles (the accounting cost of acquisitions) rose to $163 million from $138 million.

Below operating profit, things got worse. Interest expense rose to $203 million from $189 million. "Other income" fell to $5 million from $31 million a year earlier. Pretax income fell 5.4%. The tax charge was flat at $76 million, a slightly higher rate (19.7% vs 18.6%) on lower profit.

The affiliate line did the lifting. "Equity in earnings of unconsolidated affiliates", IQVIA's share of profit in companies it part-owns, was $42 million against nothing a year ago. Without it, income before that line fell 6.6% (to $310 million from $332 million). The release does not say what produced the $42 million; nine-month affiliate income is $65 million, so most of it landed in this quarter.

Buybacks explain about a third of EPS growth. Diluted shares fell 2.7% to 167.0 million, so EPS (+8.8%) grew about 3 points faster than net income (+5.7%). The cash flow statement shows $950 million of repurchases for the nine months. IQVIA's Q2 10-Q reported $950 million for the first half, so IQVIA bought back essentially no stock in the third quarter. It paid no dividend. Holding back on buybacks helped net debt fall to $13,818 million from $14,090 million in June, and net leverage (net debt divided by trailing-year Adjusted EBITDA) eased to 3.45x from 3.59x. That is still a lot of debt.

The adjusted figures exclude recurring costs. Adjusted EPS of $3.34 is 59% above GAAP EPS of $2.10. The gap is mostly acquisition amortization ($163 million), stock-based compensation ($83 million) and restructuring and related costs ($41 million). Stock-based pay is a real cost paid every quarter, and it grew 51%. Restructuring has appeared in every quarter of 2026 ($150 million so far this year). The adjusted figure also removes the $42 million affiliate gain, so on that one item adjusted EPS is the more conservative number.

Cash conversion was fine, cash growth was not. Operating cash flow was $825 million, about 2.4 times net income, which is normal for a company with large non-cash amortization and stock-based pay. But it fell 9.1% from $908 million, and free cash flow (operating cash flow minus capital spending) fell 13.6% to $667 million. For the nine months, free cash flow was $1,518 million, up only 1.9%. Receivables and unbilled services fell to $3,293 million from $3,400 million at year-end while revenue grew, so there is no sign of revenue being booked ahead of cash.

On balance the quarter is flattered: EPS rose 8.8% but pretax income fell 5.4%. A $42 million affiliate gain that did not exist a year ago and a 2.7% lower share count carried the growth, while higher restructuring and weaker other income pulled the other way by about as much as the affiliate gain helped.

Did last time's read hold up?

Our Q2 report named three things to watch in Q3:

• R&DS growth excluding pass-through costs moving closer to the headline rate: it did not. The gap was 6.8% vs 8.7% this quarter, about the same as Q2's 6.7% vs 8.8%.
• Bookings staying above revenue after a record quarter: yes. Book-to-bill was 1.2x on $3.2 billion of bookings, up 15%.
• Restructuring charges starting to fall: partly. Restructuring costs dropped to $36 million from $63 million in Q2, but they were still above last year's $20 million, and the operating-cost pressure moved to SG&A and stock-based pay instead.

Guidance and outlook

IQVIA raised its full-year 2026 guidance again:

The revenue midpoint rose $50 million, to $17,425 million. But the guidance now assumes 2.5 points of growth from acquisitions (including deals expected to close by year-end), up from 2.0 points in July. Half a point of IQVIA's roughly $16 billion 2025 revenue base is about $80 million, more than the $50 million raise. By our arithmetic, the implied organic growth for the year edged down slightly, and the higher guidance comes from acquisitions.

With nine-month revenue at $12,947 million and adjusted EPS at $9.38, the full-year ranges imply fourth-quarter revenue of about $4.40–4.55 billion and adjusted EPS of $3.52–3.62. IQVIA holds an Investor Day on December 1, 2026, where longer-term targets are likely.

Takeaway: The clinical business is in better shape than GAAP earnings show: bookings beat revenue for a second quarter and backlog due to convert in the next year is up 10%. But GAAP profit growth came from a $42 million affiliate gain and a smaller share count rather than from operations. The full-year guidance raise also came from acquisitions, not from organic growth.

What to watch in Q4: whether the next-twelve-months backlog conversion (+10%) turns into faster R&DS revenue growth excluding pass-through costs; whether the $42 million affiliate income repeats or was a one-time item (the 10-Q should explain it); whether Commercial Solutions growth recovers from 6.9%; and whether buybacks resume or IQVIA keeps using its cash to pay down debt and fund acquisitions.